证券代码：301075 证券简称：多瑞医药 公告编号：2026-015 西藏多瑞医药股份有限公司 关于王庆太、曹晓兵要约收购结果暨股票复牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 3、本次要约收购完成后，收购人及其一致行动人共计持有多瑞 医药 43,120,000 股股份，占上市公司总股本的 53.90%，公司股权分 布仍符合上市条件，上市地位不受影响。 公司于 2026 年 1 月 21 日披露了《西藏多瑞医药股份有限公司要 约收购报告书》（以下简称"要约收购报告书"），收购人向除收购人及 其一致行动人以外的公司全体股东发出部分要约，预定要约收购股份 数量为 19,440,000 股，占上市公司总股本的 24.30%，要约收购价格 为 32.07 元/股，要约收购期限为 2026 年 1 月 22 日至 2026 年 2 月 24 日。 截至 2026 年 2 月 24 日，本次要约收购期限届满，现将本次要约 收购结果公告如下： 一、本次要约收购的基本情况 1、收购人：王庆太、曹晓兵 2、被收购公司名称：西藏多瑞医药股份有限公司 3、被收购公司 ...

Group 1 - The company's stock will resume trading on February 27, 2026 [1] - During the tender offer period from January 22, 2026, to February 24, 2026, shareholder accounts that accepted the offer totaled 3, with a total of 17.60 million shares accepted by Wang Qingtai [1] - Another 4 shareholder accounts accepted the offer from Cao Xiaobing, totaling 1.85 million shares [1] Group 2 - After the completion of the tender offer, the acquirer and its concert parties will hold a total of 43.12 million shares in the company, representing 53.90% of the total share capital [1]

Performance Summary - Supor reported a net profit of 2.097 billion yuan for 2025, a decrease of 6.58% year-on-year [2] - Sanofi reported a net profit of 2.939 billion yuan for 2025, an increase of 317.09% year-on-year [17] - Wens Foodstuff Group reported a net profit of 5.235 billion yuan for 2025, a decrease of 43.59% year-on-year [18] - Sree New Materials reported a net profit of 154 million yuan for 2025, an increase of 35.04% year-on-year [22] - JiaoKong Technology reported a net profit of 156 million yuan for 2025, an increase of 86.13% year-on-year [22] - Aidi Pharmaceutical reported a net loss of 19.7337 million yuan for 2025, a reduction in loss [22] - MicroGuide Nano reported a net profit of 213 million yuan for 2025, a decrease of 6.12% year-on-year [22] - Zhongwei Semiconductor reported a net profit of 285 million yuan for 2025, an increase of 108.05% year-on-year [22] - Hengyu Environmental reported a net profit of 35.9325 million yuan for 2025, an increase of 106.25% year-on-year [22] - Zhongke Shuguang reported a net profit attributable to shareholders of 2.113 billion yuan for 2025, an increase of 10.54% year-on-year [22] - Oat Technology reported a net profit of 137 million yuan for 2025, an increase of 42.63% year-on-year [22] - Yongxi Electronics reported a net profit attributable to shareholders of 82.2403 million yuan for 2025, an increase of 23.99% year-on-year [22] Shareholding Changes - Asia Optical's shareholders plan to reduce their holdings by no more than 1.6 million shares [22] - Anhui Conch Cement's controlling shareholder plans to increase its holdings by 700 million to 1.4 billion yuan [22] - Huaneng Hydropower's controlling shareholder plans to increase its holdings by 100 million to 150 million yuan [22] - Fushi Holdings' shareholders plan to reduce their holdings by no more than 2% [22] - Zhixin Precision's board members plan to reduce their holdings by no more than 1.8562% [22] - Hongbaoli's deputy general manager plans to reduce their holdings by no more than 310,000 shares [22] - Yuanli Co. plans to repurchase shares worth 50 million to 60 million yuan [22] - Zhongshun Jierou plans to repurchase shares worth 60 million to 120 million yuan [22] Contract Awards - Fengfan Co. won a procurement project from Southern Power Grid worth approximately 184 million yuan [22] - Shaoneng Co.'s wholly-owned subsidiary signed a cooperation agreement for land and resources for an independent energy storage power station project with Yuancan Company [22] Major Investments - Zhejiang Medicine plans to invest 250 million yuan in a silver economy fund in collaboration with a private equity fund [4] Project Approvals - Gansu Energy's Minqin Shuangchike 2 million kilowatt wind power project has been approved [5] - China Tianying received investment approval for the expansion of its Hanoi project [5] Mergers and Acquisitions - Dazhu Laser plans to invest 150 million USD to establish an overseas operation center [6] - Dongyang Sunshine is planning to acquire control of Dongshu No. 1, with stock suspension [6] - Shenlian Bio plans to acquire control of Shizhi Source for 237 million yuan to fully develop its innovative drug business [23] - Tongwei is planning to purchase 100% of Lihua Qingneng, with stock suspension starting tomorrow [23] - Changxin Bochuang plans to acquire 93.8108% of Shanghai Honghui Optical Communication Technology Co., Ltd. for 375 million yuan [23] - Kaipu Cloud has terminated the acquisition of 100% of Nanning Taike [23] Other Developments - Kexin Mechanical and Electrical obtained a production license for ultra-high pressure containers (A6) [10] - Baiyin Nonferrous Metals received a government subsidy of 9 million yuan [24] - Rundou Co. received a drug registration certificate for ibuprofen tablets [25] - Hengrui Medicine's application for the marketing authorization of the innovative drug SHR-1918 injection has been accepted and included in the priority review process [26] - Duorui Medicine's tender offer period has expired, and the company's stock is suspended [27] - Inner Mongolia Huadian plans to apply for a change of its stock name to "Huaneng Mengdian" [28]

Regulatory Updates - The National Medical Products Administration (NMPA) has released the "Guidelines for Pharmaceutical Research on Chemical Drugs for Rare Diseases (Trial)" to enhance support for rare disease drug development and improve technical guidance principles [1] - Hengrui Medicine's innovative drug SHR-1918 injection has been accepted for priority review by the NMPA, aimed at treating patients with homozygous familial hypercholesterolemia [1] - CanSino Biologics has expanded the age range for its ACYW135 meningococcal polysaccharide conjugate vaccine from children aged 3 months to 3 years to those aged 3 months to 6 years, which is expected to positively impact the company's performance [2] - Tongrentang Pharmaceutical has received product registration approval from Health Canada for several products, including children's cough syrup, although further administrative approvals are required for sales [3] - Shanghai Pharmaceuticals has obtained a drug registration certificate in Singapore for rivaroxaban tablets, which are used to reduce the risk of stroke and systemic embolism in non-valvular atrial fibrillation patients [4] - Baotai has received acceptance for the marketing authorization application of its drug BAT4406F, intended for treating adult patients with AQP4 antibody-positive neuromyelitis optica spectrum disorder [5] Industry Developments - Zhejiang Medicine plans to invest 250 million yuan in a silver economy fund in collaboration with a private equity fund, focusing on the healthcare sector [6] - Zhijiang Biology has completed a strategic increase in its stake in Sanyou Biopharmaceuticals, enhancing its position in the precision medicine sector [7] - Xianweida Biopharmaceutical has entered a commercialization agreement with Pfizer China for its GLP-1 receptor agonist, which could yield up to $495 million in payments [8] Financial Performance - Sangfor Technologies reported a projected net profit increase of 317.09% for 2025, driven by a significant collaboration with Pfizer that resulted in a revenue recognition of approximately 2.89 billion yuan [9] Capital Market Activities - Duorui Pharmaceuticals announced a stock suspension following the expiration of a tender offer period, pending confirmation of the offer results [10] - Jiutian Pharmaceutical completed a share buyback of 1.24% of its total shares, with a total transaction amount of 100 million yuan [11] - Shenlian Biopharmaceutical plans to acquire controlling interest in Shiziyuan Biotechnology for 237 million yuan, aiming to expand into innovative drug business [12]

Performance Highlights - Sanofi's net profit for 2025 increased by 317.09% year-on-year, reaching 2.939 billion yuan, with total revenue of 4.199 billion yuan, a growth of 251.81% [5] - Zhongwei Semiconductor reported a net profit increase of 108.05% year-on-year for 2025, totaling 285 million yuan, with total revenue of 1.122 billion yuan, up 23.09% [5] - Jiaokong Technology's net profit rose by 86.13% year-on-year to 156 million yuan, with total revenue of 2.537 billion yuan, an increase of 16.08% [6] - Supor's net profit decreased by 6.58% year-on-year to 2.097 billion yuan, with total revenue of 22.772 billion yuan, a growth of 1.54% [6] - Wens Foodstuff Group's net profit fell by 43.59% year-on-year to 5.235 billion yuan, with total revenue of 103.884 billion yuan, down 1.67% [6][7] Mergers and Acquisitions - Tongwei Co., Ltd. is planning to acquire 100% equity of Qinghai Lihua Qingneng, with stock suspension starting from February 25, 2026, for up to 10 trading days [2] - Changxin Bochuang intends to acquire 93.8108% equity of Shanghai Honghui Optical Communication Technology Co., with a preliminary price of 375 million yuan [3] Major Events - Light Media reported revenue from the film "Fast and Furious 3" between 43 million to 53 million yuan as of February 23, 2026 [4] - Zhongshun Jierou plans to repurchase shares worth between 60 million to 120 million yuan [9] - Yuanli Co. plans to repurchase shares worth between 50 million to 60 million yuan [10] Capital Increase and Restructuring - Dongyangguang is planning to acquire control of Yichang Dongshu No. 1 Investment Co. through a share issuance, with stock suspension starting from February 24, 2026 [8] - ST Renfu plans to raise 3 billion to 3.5 billion yuan through a private placement to fund various projects [8] Shareholding Changes - Conch Cement's controlling shareholder plans to increase holdings between 700 million to 1.4 billion yuan [12] - Huaneng Hydropower's controlling shareholder plans to increase holdings between 100 million to 150 million yuan [12]

Major Announcements - Light Media's film "Fast and Furious 3" has achieved a cumulative box office revenue of approximately 2.926 billion yuan, with the company's revenue from this film estimated between 43 million to 53 million yuan, which exceeds 50% of the company's audited consolidated financial statement revenue for the most recent fiscal year [1] - Dazhong Laser plans to invest 150 million USD to establish an overseas operation center in Southeast Asia to enhance service capabilities and meet international market demands [1] - Shunlian Bio intends to acquire controlling interest in Yanzhou Shizhi Source Biotechnology Co., Ltd. for 237 million yuan, aiming to fully develop its innovative drug business [2] - Shaoneng Co. signed a cooperation agreement with Yuancan Company for an independent energy storage power station project, with a total agreement amount of 22 million yuan [3] - China Tianying received investment approval for the expansion of its waste-to-energy project in Hanoi, with an investment amount of approximately 220 million USD [4] - Gansu Energy's 2 million kW wind power project has received approval from the local development and reform bureau [5] - Kexin Machinery obtained a production license for ultra-high pressure vessels [6] Financial Performance - Zhongwei Semiconductor reported a net profit of 285 million yuan for 2025, a year-on-year increase of 108.05%, with total revenue of 1.122 billion yuan, up 23.09% [9] - Weidao Nano reported a net profit of 213 million yuan for 2025, a year-on-year decrease of 6.12%, with total revenue of 2.632 billion yuan, down 2.52% [10] - Wens Foodstuff Group reported a net profit of 5.235 billion yuan for 2025, a year-on-year decrease of 43.59%, with total revenue of 103.884 billion yuan, down 1.67% [11] - SanSheng Guojian reported a net profit of 2.939 billion yuan for 2025, a year-on-year increase of 317.09%, with total revenue of 4.199 billion yuan, up 251.81% [12] - Yongxi Electronics reported a net profit of 82.24 million yuan for 2025, a year-on-year increase of 23.99%, with total revenue of 4.4 billion yuan, up 21.92% [14] - YaoMai Technology reported a net profit of 137 million yuan for 2025, a year-on-year increase of 42.63%, with total revenue of 619 million yuan, up 24.33% [15] - Zhongke Shuguang reported a net profit of 2.113 billion yuan for 2025, a year-on-year increase of 10.54%, with total revenue of 14.97 billion yuan, up 13.86% [15] Shareholder Actions - Zhongshun Jierou plans to repurchase shares worth between 60 million to 120 million yuan for employee stock ownership plans [21] - Yuanli Co. plans to repurchase shares worth between 50 million to 60 million yuan for stock incentive plans [21] - Huaneng Hydropower's controlling shareholder plans to increase its stake by 100 million to 150 million yuan [22] - Conch Cement's controlling shareholder plans to increase its stake by 700 million to 1.4 billion yuan [23] Stock Suspension - Dongyangguang announced a stock suspension due to plans to acquire control of Dongshu No. 1 [29] - Tongwei Co. announced a stock suspension due to plans to acquire 100% equity of Qinghai Lihua Qingneng [30] - Duorui Pharmaceutical announced a stock suspension as the offer period for its acquisition has expired [31]

Group 1 - Dongyangguang is planning to acquire control of Yichang Dongshu No. 1 Investment Co., Ltd. through a share issuance, leading to a stock suspension starting February 24, 2026, for up to 10 trading days [1] - Tongde Chemical has received an execution notice and ruling, resulting in the freezing and deduction of bank deposits amounting to RMB 53.93 million [2] - Palm Holdings is facing a lawsuit for a construction contract dispute with a claim amount of RMB 113 million, which represents 6.83% of the company's latest audited net assets [3] Group 2 - Duorui Pharmaceutical's tender offer period has expired, leading to a stock suspension starting February 25, 2026, after a tender offer for 19.44 million shares at RMB 32.07 per share [4] - Huazhi Media reported that the film "Silent Awakening" has grossed approximately RMB 901 million, exceeding 50% of the company's latest audited annual revenue [5] - Light Media announced that the film "Racing Life 3" has grossed about RMB 2.926 billion, also exceeding 50% of the company's latest audited annual revenue [6][7] Group 3 - Tongwei Co. is planning to acquire 100% of Lihua Qingneng Co., Ltd. through a combination of share issuance and cash payment, with a stock suspension starting February 25, 2026, for up to 10 trading days [8] - Meibang Co. confirmed that its operations are normal and there are no undisclosed significant information despite a stock price fluctuation exceeding 20% [9] - China Nuclear Construction's shareholder, China Cinda, has reduced its holdings by 8.0354 million shares, accounting for 0.2666% of the total share capital [10] Group 4 - Changxin Bochuang intends to acquire 93.81% of Shanghai Honghui Optical Communication Technology Co., Ltd. for a tentative price of RMB 375 million, aiming to enhance its capabilities in the optical communication sector [11] - Beingmei has had its patent contract dispute case accepted, with claims amounting to RMB 56.85 million, while also facing a counterclaim of RMB 77.25 million [12] Group 5 - Several companies have reported their 2025 net profit forecasts, with notable increases such as SanSheng Guojian at RMB 2.939 billion, a 317.09% increase year-on-year, while Wens Foodstuffs reported a decline of 43.59% to RMB 5.235 billion [13]

Group 1 - Hengyu Environmental reported a revenue of 294 million yuan for 2025, an increase of 89.87%, and a net profit of 35.93 million yuan, up 106.25% year-on-year [1] - Yongxi Electronics achieved a revenue of 4.4 billion yuan in 2025, a growth of 21.92%, with a net profit of 82.24 million yuan, reflecting a year-on-year increase of 23.99% [2] - Zhongwei Semiconductor reported a revenue of 1.122 billion yuan for 2025, a 23.09% increase, and a net profit of 285 million yuan, up 108.05% year-on-year [3] - Sry New Materials achieved a revenue of 1.564 billion yuan in 2025, a growth of 17.66%, with a net profit of 154 million yuan, reflecting a year-on-year increase of 35.04% [14] - Jiaokong Technology reported a revenue of 2.537 billion yuan for 2025, a growth of 16.08%, and a net profit of 156 million yuan, up 86.13% year-on-year [15] - SanSheng Guojian reported a revenue of 4.199 billion yuan for 2025, a significant increase of 251.81%, with a net profit of 2.939 billion yuan, up 317.09% year-on-year [30] Group 2 - Aidi Pharmaceutical reported a revenue of 721 million yuan for 2025, a growth of 72.49%, but incurred a net loss of 19.73 million yuan, reducing losses from 142 million yuan in the previous year [5] - Weidao Nano reported a revenue of 2.632 billion yuan for 2025, a decrease of 2.52%, with a net profit of 213 million yuan, down 6.12% year-on-year [9] - Wens Foodstuff Group reported a revenue of 103.884 billion yuan for 2025, a decline of 1.67%, with a net profit of 5.235 billion yuan, down 43.59% year-on-year [29] - Supor reported a revenue of 22.772 billion yuan for 2025, a growth of 1.54%, with a net profit of 2.097 billion yuan, down 6.58% year-on-year [33] Group 3 - ShaoNeng Co. signed a significant operational contract worth 22 million yuan for a biomass power generation project [6] - Shunlian Bio plans to use 237 million yuan to acquire controlling interest in a joint venture, increasing its stake from 16.99% to 51% [7] - Huason Pharmaceutical's subsidiary received clinical trial approval for an innovative drug, indicating progress in its product pipeline [8] - Xinyang Technology's subsidiary received a medical device registration certificate, enhancing its product offerings [10][11] - Yida Co. obtained an investment project filing certificate for a chemical production project with a total investment of 642 million yuan [12]

多瑞医药（301075）(301075.SZ)公告，公司于2026年1月21日披露了王庆太、曹晓兵送达的《西藏多瑞 医药股份有限公司要约收购报告书》，收购人向除收购人及其一致行动人以外的公司全体股东发出的部 分要约，要约价格为32.07元/股，要约收购股份数量1944万股，占公司总股本的24.30%。本次要约收购 期限为2026年1月22日至2026年2月24日。截至2026年2月24日，本次要约收购期限已届满。鉴于本次要 约收购结果需进一步确认，公司股票自2026年2月25日(星期三)上午开市起停牌，并将在要约收购结果 公告日开市起复牌。 ...

智通财经APP讯，多瑞医药(301075.SZ)公告，公司于2026年1月21日披露了王庆太、曹晓兵送达的《西 藏多瑞医药股份有限公司要约收购报告书》，收购人向除收购人及其一致行动人以外的公司全体股东发 出的部分要约，要约价格为32.07元/股，要约收购股份数量1944万股，占公司总股本的24.30%。本次要 约收购期限为2026年1月22日至2026年2月24日。截至2026年2月24日，本次要约收购期限已届满。鉴于 本次要约收购结果需进一步确认，公司股票自2026年2月25日(星期三)上午开市起停牌，并将在要约收 购结果公告日开市起复牌。 ...